Skip to main content
Fig. 3 | BMC Women's Health

Fig. 3

From: Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study

Fig. 3

Percent changes from baseline in the serum concentration of bone turnover markers, BAP (a) and NTX (b). Open and closed circles indicate the switching group (group 1) and continuous MIN group (group 2), respectively. Data are shown as mean ± standard error. ##P < 0.01 change from baseline within each treatment group. **P < 0.01 group 1 versus group 2

Back to article page